Introduction
The most commonly used cancer therapeutics eliminate tumours by inducing apoptosis (Herr and Debatin, 2001; Johnstone et al., 2002) . Overexpression or loss of function of some anti-apoptotic proteins, notably those from the Bcl-2 family (Box 1), have a rather large spectrum of apoptosis-inhibitory effects and confer a multidrug resistance phenotype (Kroemer, 1997) , and the major Bcl-2-controlled checkpoint is mitochondrial membrane permeabilization (MMP) (Kroemer, 1997) .
One of the signature events of apoptotic autolysis consists in the activation of a cascade of proteolytic enzyme, the so-called caspases, which are synthesized as zymogens (pro-caspases) and undergo proteolytic maturation. Caspase activation can be achieved by the occupation of so-called 'death receptors' (DR) from the tumour necrosis factor (TNF) receptor superfamily (e.g. CD95/Apo-1/Fas, DR3, DR4), which, once ligated, stimulate the recruitment of a specific subclass of activator pro-caspases (in particular pro-caspases -8 and -10), leading to their receptor-proximal activation (Box 2). In some cell types ('type 1 cells'), the resulting caspase-8 activation fully turns on the caspase activation cascade by proteolytic activation of pro-caspase-3, the principal effector caspase. In most cell types ('type 2 cells'), however, death receptor crosslinking fails to cause a caspase-8 activation that would be sufficiently strong to activate caspase-3. Rather, the pathway involves the caspase-8 mediated digestion of the Bcl-2 family protein Bid (which yields truncated Bid, t-Bid), t-Bid-mediated mitochondrial membrane permeabilization (MMP), release of cytochrome c from mitochondria, and cytochrome c-dependent formation of a caspase-3 activation complex, the apoptosome. Chemotherapy can induce the expression of death receptors and/or their ligands and thus activate the 'extrinsic' pathway which then kills cells in an MMPindependent ('type 1') or in an MMP-dependent ('type 2') fashion . In addition and probably more important, chemotherapy can elicit cellular stress which ultimately leads to caspaseindependent MMP, through the 'intrinsic' pathway (Costantini et al., 2000b) . In this latter paradigm, Bcl-2-inhibitable MMP seals the cell's fate, leading to death with or without post-mitochondrial caspase activation Kroemer and Reed, 2000) .
Tumours become resistant to treatment by modifying expression levels or function of proteins involved in this apoptosis signalling pathway. Inactivation of p53, either directly through p53 mutations or indirectly through p53 modulators such as the mdm2 protein, occurs in most human cancers. Without p53 function, tumour cells evade apoptosis and can continue to proliferate, despite genetic instabilities caused by chemotherapy or irradiation. Many cancer cells overexpress anti-apoptotic proteins such as Bcl-2 (Kroemer, 1997) . Studies in breast and gastrointestinal tumours, as well as other cancer types, have shown that loss of Bax expression, or increased expression of Bcl-2 or Bcl-X L, are associated with poor prognosis and decreased response to chemotherapy (Ionov et al., 2000; Paradiso et al., 2001; Sturm et al., 2001; Tai et al., 1998) . Since these pro-apoptotic signalling pathways eventually lead to MMP, direct activation of this process might be able to circumvent chemotherapy resistance caused by mutations in pre-mitochondrial signal-transducing machinery. But how does MMP actually occur, and how can we induce it specifically in cancer cells?
Mitochondrial membrane permeabilization (MMP): the apoptotic checkpoint
Numerous pro-apoptotic pathways converge at the level of MMP induction, and MMP may have multiple lethal consequences for cellular physiology, suggesting that MMP may function as the 'central executioner' of apoptosis (Green and Kroemer, 1998) .
Mitochondria as death signal integrators Mitochondria integrate numerous different pro-apoptotic signal transducing pathways (Table 1) . Prominent proteins which translocate to mitochondria upon apoptosis induction include the pro-apoptotic members of the Bcl-2 family (Adams and Cory, 2001; Gross et al., 1999; Kroemer, 1997; Martinou and Green, 2001; Vander Heiden and Thompson, 1999; Zamzami and Kroemer, 2001 ). Thus, Bax translocates from the cytosol to mitochondria in response to multiple different apoptosis inducers. One mechanism triggering Bax translocation is cytosolic alkalinization (which can be triggered by growth factor withdrawal) (Khaled et al., 2001) . Bax translocation is linked to a conformational change, insertion into the mitochondrial membranes, and oligomerization. Bid is also normally found in the cytosol and can be cleaved by proteases (in particular by caspase-8 but also by calpain, cathepsin L, or granzyme B) to become truncated Bid (t-Bid), a pro-apoptotic molecule. This reaction depends on the activation state of caspase-8, the presence of specific caspase-8 inhibitors, as well as on post-translational modifications of Bid. Phosphorylation of Bid by casein kinases 1 or 2 prevents its cleavage by caspase-8 (Desagher et al., 2001 ). t-Bid, which is rapidly N-myristoylated (Zha et al., 2000) , then translocates to mitochondrial membranes, exemplifying how pre-mitochondrial signal transduction can be controlled at several levels.
Similar mitochondrial translocation events have been reported for other pro-apoptotic Bcl-2 family members including Bad (which is cytosolic when phosphorylated, for instance by the pro-survival kinase Akt/PKB and mitochondrial when dephosphorylated) (Chao and Korsmeyer, 1998) , Bim (which is normally associated with the dynein light chain) (Puthalalath et al., 1999) , Bmf (normally associated with the myosin V actin motor complex) (Puthalakath et al., 2001) , BNIP3 (which is transcriptionally activated by hypoxia) (Sowter et al., 2001) , as well as NoxA, PUMA and Bbc3 (all transcriptionally activated by p53, as Bax) (Han et al., 2001; Oda et al., 2000a) . Other interesting pro-apoptotic, p53-induced gene products acting on mitochondria are oxidoreductases (proline oxidase and ferredoxin reductase), which are imported into mitochondria and locally increase the production of ROS, the mitochondrial matrix protein p53AIP1, which can dissipate the mitochondrial tnansmembrane potential (DC m ) (Donald et al., 2001) , and the Peutz-Jegher gene product LKB1, a serine/threonine kinase translocating to mitochondria (Karuman et al., 2001) . In addition, p53 (and other transcription factors such as TR3), as well as different kinases (SEK1, JNK, PKC-d, c-Abl) reportedly translocate to mitochondria during early apoptosis (Aoki et al., 2002; Kumar et al., 2001; . All these proteins may induce MMP. Divalent cations (in particular Ca 2+ ), reactive oxygen species (ROS), nitric oxide, and a number of different (sphingo)lipid second messengers (in particular ganglioside GD3) can also act on mitochondria to cause MMP . In view of this multitude of pro-apoptotic stimuli acting on mitochondria, it is not surprising that a number of different proteins and metabolites exert local mitochondrioprotective effects (Table 2 ). This applies in particular to the antiapoptotic proteins from the Bcl-2 family (Bcl-2, Bcl-X L ), certain enzymes involved in intermediate metaBox 2 Two alternative pathways elicited by chemotherapy. Intrinsic pathway (or stress pathway): Through a variety of direct or indirect mechanisms, chemotherapy leads to mitochondrial membrane permeabilization, which is regulated, at least to some extent, by proteins from the Bcl-2 family. Mitochondrial membrane permeabilization is rate limiting for cell death. Caspase activation is elicted by the intrinsic pathway yet is mostly dispensable for cell death to occur. Experimental chemotherapeutic agents directly inducing MMP are being developed (Table 4) . Extrinsic pathway: (DR) of the tumour necrosis factor (TNF) receptor superfamily (e.g. CD95/Apo-1/Fas, DR3, DR4) and/or their ligands are induced at the transcriptional and/or post-transcriptional levels. DR ligation stimulates the recruitment and activation of a specific subclass of activator pro-caspases, in particular caspases 8 and 10. Inhibition of the activation of these initiator caspases results in cell death inhibition. The subsequent steps leading to apoptosis depend on the cell type: * Type 1 cells : DR binding leads to caspase-8 (or -10) activation, resulting in direct proteolytic activation of pro-caspase-3 -the principal effector caspase -and initiation of the caspase cascade. In type 1 cells, overexpression fails to prevent caspase activation and apoptosis. Type 1 cell death elicited via DR reportedly occurs independent from mitochondrial membrane permeabilization. * Type 2 cells : DR crosslinking fails to induce a level of caspase-8 activation sufficient to activate caspase-3. Rather, the pathway involves the caspase-8 mediated digestion of the Bcl-2 family protein Bid (which yields truncated Bid, t-Bid), t-Bid-mediates mitochondrial membrane permeabilization, release of cytochrome c from mitochondria, and cytochrome c-dependent formation of a caspase-3 activation complex, the apoptosome. Inhibition of mitochondrial membrane permeabilization by Bcl-2 prevents apoptosis in type 2 cells.
bolism (e.g. hexokinase II, which hinders Bax from inserting into mitochondrial membranes), certain kinases (e.g. protein kinase A, which phosphorylates and inactivates Bad), anti-oxidant enzymes, as well as to energy-rich metabolites (glucose, ATP, ADP, NADH + ), implying a major cross-talk between signal transduction, redox regulation and intermediate metabolism at the mitochondrial level.
How MMP coordinates multiple aspects of apoptosis MMP variably affects the outer (OM) and inner mitochondrial membranes (IM), respectively (Box 3). IM permeabilization is rather partial causing the retention of most if not all matrix proteins, while OM permeabilization leads to the release of soluble apoptogenic proteins from the intermembrane space (Table 3) . Several among these proteins are involved in . Co 2+ quenches extra-mitochondrial calcein, yet does not penetrate into the matrix compartment as long as the IM membrane remains intact. Thus, the presence of a matix calcein signal indicates an impermeable IM and loss of the signal indicates IM permeabilization. (c) Changes in mitochondrial membrane lipid content can be detected by staining with the cardiolipin-specific dye nonyl acridine orange (NAO). (d) Ultrastructural analysis of cells with conventional transmission electron microscopy (two-dimensional vision) or computer-aided tomographic electron microscopy (three-dimensional reconstruction) is the most definitive method of detecting MMP.
Example 1: Redistribution of AIF from the mitochondrial intermembrane space to the nucleus during apoptosis. Normal or etoposide-treated apoptotic Hela cells were stained with an antibody specific for the resident mitochondrial protein Hsp60, an antibody specific for AIF, and Hoechst 33324 which stains chromatin.
Example 2: Analysis of the DC m in circulating tumour cells from a patient with acute lymphoblastic leukaemia (ALL) before (a) and after (b) treatment with prednisolon for 3 days (BFM protocol). Leukemia cells stained ex vivo with phycoerythrine (PE)-labelled anti-CD19 and with the DC m -sensitive dye DiOC(6)3 were analysed immediately after isolation from the patient. the activation of caspases. Cytochrome c, a heme protein responsible for electron transfer between complexes III and IV of the respiratory chain, is usually confined to mitochondria where it undergoes electrostatic interactions with the outer side of IM. Cytochrome c release from mitochondria does not only rely on MMP but also requires its detachment from the IM-specific lipid, cardiolipin (Ott et al., 2002) . Once released to the cytosol, cytochrome c interacts with Apaf-1, ATP, and pro-caspase-9 to form a molecular caspase activation complex, the apoptosome, which catalyzes the proteolytic maturation of caspase-3, the principal effector caspase (Budijardjo et al., 1999) . Depending on the cell type, mitochondria contain variable amounts of pro-caspases (e.g. pro-caspases-2, -3, and -9), which are released upon apoptosis induction (Susin et al., 1999a) . One of these procaspases, pro-caspase-3, is normally S-nitrosylated on its catalytic Cys residue, when present in mitochondria. Upon apoptosis induction, pro-caspase-3 is de-nitrosylated and released (Mannick et al., 2001) . Smac/ DIABLO is another interesting pro-apoptotic protein normally confined to mitochondria. Upon import of the Smac/DIABLO precursor into the intermembrane space, the N-terminal mitochondrial localization sequence (MLS) is removed, thereby unmasking a new N-terminus (AVPIAQ...). Once released, the Nterminus of Smac/DIABLO interacts with and neutralizes the protein XIAP, an inhibitor of caspases-3 and -9. Thus Smac/DIABLO facilitates caspase activation Verhagen et al., 2000) . A similar Nterminus (AVPSPP....) found in the intermembrane protein Htra2/Omi also binds and neutralizes to XIAP. In addition, Htra2/Omi is a serine protease and can induce cell death through its catalytic properties (Suzuki et al., 2001) . AIF is an intermembrane flavoprotein with NADH + reductase activity which, after apoptosis induction, translocates to the nucleus where it can trigger peripheral chromatin condensation through a yet unknown mechanism (Susin et al., 1999b) . Another mitochondrial protein which translocates to the nucleus is endonuclease G . Finally, it may be speculated that the release of IkBa may contribute to the inactivation of the cytoprotective transcription factor NF-kB (Bottero et al., 2001) .
Altogether, it appears that the mitochondrion is a sort of poison cupboard replete with potentially lethal proteins which, after MMP, translocate to different cellular localizations and participate in cellular demise. As a consequence of apoptotic MMP, mitochondria sooner or later lose their vital metabolic and redox functions, their mitochondrial inner transmembrane potential (DC m ), as well as their capacity to act as Ca 2+ storage organelles. The consequent depletion of ATP and oxidative reactions contribute to cell death.
MMP as an apoptotic checkpoint One particularly intriguing feature of MMP consists in the fact that several of its consequences can stimulate MMP, implying a positive amplification loop. Thus, Ca 2+ can trigger mitochondria to release Ca 2+ (Ichas et al., 1997) . ROS induce mitochondria to produce ROS (Zorov et al., 2000) . Caspases activated as a consequence of MMP digest the latent MMP inducers Bid and Bad, thereby activating them, and degrade the MMP inhibitors Bcl-2 and Bcl-X L , converting them into MMP inducers . AIF released from mitochondria can stimulate MMP (Susin et al., 1999b) . These features may explain why MMP occurs mostly in an all-or-nothing fashion, as a consequence of a rapid irreversible process that, in large cells, can proceed in a wave-like fashion. Altogether, it thus appears that MMP is induced by a cornucopia of different apoptosis inducers, that it has multiple lethal consequences and that it is closely linked to or, perhaps, identical with the point-of-noreturn of the cell death process. MMP is rate-limiting for cell death induction in most situations, even when the primary cell death inducer affects plasma membranes (e.g. in type II cells in death receptor signalling) (Scaffidi et al., 1998) , the nucleus (e.g. in p53-dependent stress pathways) (Vogelstein et al., 2000) or other organelles including the endoplasmic reticulum Wei et al., 2001 ) and lysosomes Stoka et al., 2001 ). MMP appears to be the (or one of the) checkpoint(s) determining entry into apoptosis. 
Mechanisms and regulation of MMP
In view of the role of MMP for apoptosis control, it is of the utmost importance to understand its regulation at the molecular level. Although many of the molecular actors regulating MMP are known (Tables 1 and 2) , the exact mechanisms of MMP are highly controversial (Martinou and Green, 2001; Zamzami and Kroemer, 2001 ). This applies in particular to the question of which mitochondrial proteins are actually functioning as non-specific pores and which are mere pore regulators. Even worse, there is an ongoing controversy whether and to what extent mitochondrial ultrastructure is altered during apoptosis. Moreover, the temporal and functional order OM and IM permeabilize may well depend on the primary apoptosis inducer. For the purpose of this review, we will briefly discuss the most important MMP-regulatory molecules ( Figure  1 ).
Bax and Bak
Mouse embryonic fibroblasts (MEF) lacking both Bax and Bak, two tumour suppressor gene products, are resistant to a plethora of different apoptotic stimuli including t-Bid, Bim, Bad, Noxa, staurosporine, ultraviolet radiation, growth factor deprivation, etoposide, oxygen deprivation, and the endoplasmic reticulum stress stimuli thapsigargin and tunicamycin McClintock et al., 2002; Wei et al., 2001; Zong et al., 2001) . Such cells are more susceptible to Ras-mediated transformation than control cells . However, when treated with granzyme B, Bax 7/7 Bak 7/7 MEF undergo apoptosis and DC m loss without cytochrome c release, indicating the existence of an independent mitochondrial pathway that may participate in cell death induction (Thomas et al., 2001) . Overexpression of Bax and Bak suffices to kill cells. Bak is normally associated with OM and fully inserts into OM, accompanied by a conformational change, upon apoptosis induction. In contrast to Bak, Bax is mostly found in the cytosol of healthy cells. Upon apoptosis induction, Bax translocates from the cytosol to OM where it inserts and oligomerizes ( Figure 1a ). Recombinant Bax can permeabilize liposomal membranes and form channels in planar lipid bilayers. The size of these channels is reportedly sufficient to allow for the release of proteins such as cytochrome c (Saito et al., 2000) . Moreover, Bax has also been proposed to lipid bilayers (Basan˜ez et al., 1999) . The mechanisms of membrane permeabilization induced in isolated mitochondria exposed to recombinant Bax depend on the oligomerization status of Bax. Bax monomers cause permeabilization through a pathway that can be inhibited by cyclosporin A (CsA), while Bax oligomers trigger CsA-resistant cytochrome c release (Gogvadze et al., 2001) (Figure 1a ). These findings are important in view of a long standing polemic whether Baxmediated mitochondrial membrane permeabilization relies on the capacity of Bax alone to oligomerize and to form channels (Martinou and Green, 2001) or whether Bax has to interact with other proteins. Thus, Bax has been proposed to interact with a molecular complex including the putative CsA target cyclophilin D -a mitochondrion-specific peptidyl prolyl isomerase. This interaction would explain why, at least in some cases, CsA can inhibit Bax-induced membrane permeabilization (Ju¨rgensmeier et al., 1998; Marzo et al., 1998; Zamzami and Kroemer, 2001 ).
Other Bcl-2 family members t-Bid is thought to induce apoptosis through the induction of a conformational change in Bax (or Bak), thereby triggering its full membrane insertion and oligomerization . Accordingly, Bax 7/7 Bak 7/7 MEF are relatively resistant to t-Bid-induced cytochrome c release Zong et al., 2001) . Nevertheless, it has also been suggested that t-Bid forms membraneinserted homotrimers not interacting with other mitochondrial proteins (Grinberg et al., 2002) . t-Bid can form channels in planar lipid bilayers (Schendel et al., 1999) and destabilize them (Kudla et al., 2000) . The question of whether t-Bid's effects on mitochondria depend on interactions with sessile mitochondrial proteins, including a CsA target, has been controversial (Shimizu and Tsujimoto, 2000; Zamzami et al., 2000) . A recent study indicates that t-Bid-mediated permeabilization occurs in a two-step process, the first step (CsA-independent) leading to only a partial (*15%) cytochrome c release, and the second step (CsAinhibited) causing total cytochrome c release and a remodelling of mitochondrial ultrastructure (Scorrano et al., 2002) . Other pro-apoptotic proteins from the Bcl-2 family such as Bad, Bim, and Noxa are thought to induce apoptosis via an interaction with either Bax or Bak and/or by generating stable complexes with anti-apoptotic Bcl-2/Bcl-X L (Adams and Cory, 2001; Cheng et al., 2001 ).
Voltage-dependent anion channel (VDAC) VDAC, the most abundant mitochondrial OM protein, has been reported to be required for apoptosis induction ( Figure  1b) . VDAC is normally responsible for the transport of metabolites between the cytosol and the mitochondrial intermembrane space. Microinjection of VDAC-specific antibodies or of a VDAC-specific inhibitor (Ko¨nigs's polyanion) can inhibit apoptosis induced by microinjected Bax (Ferri et al., 2000) , etoposide, paclitaxel, and staurosporine treatment (Shimizu et al., 2001a) . VDAC might be sufficient to permeabilize membranes since VDAC proteoliposomes release cytochrome c in the presence of ROS (Madesh and Hajnoczky, 2001 ). Bcl-2 and Bcl-X L have been reported to close the VDAC, both in liposomes and in plain lipid bilayers. This effect can be mimicked by peptides corresponding to the BH4 domains, which are present in Bcl-2 and Bcl-X L yet are absent from the pro-apoptotic proteins Bax, Bak, Bid, Bim and Noxa (Shimizu et al., 2000b) (Box 1). Bax or Bak (but not Bid) might interact with VDAC to create composite channels sufficiently large to release cytochrome c (Shimizu and Tsujimoto, 2000) . VDAC therefore appears to be the prime cytochrome c release channel in the OM, and its activity might be suppressed by Bcl-2 or Bcl-X L , or increased by Bax or Bak.
There is another completely different mechanism through which VDAC might participate in apoptosis induction. Upon growth factor withdrawal, the exchange of metabolites (ATP, ADP, NADH, creatine and creatine phosphate) on OM might be reduced, due to a closure of VDAC (Vander Heiden et al., 2000; Vander Heiden et al., 2001a) . Although the exact reasons for VDAC closure have not been elucidated, it has been suggested that an increased IM transmembrane potential (DC m ) would directly affect OM, creating a local voltage gradient and closure of VDAC. This OM DC causing closure of VDAC would be dissipated by During an early step of apoptosis, the translocase activity of ANT is inhibited and later ANT can convert into a nonspecific pore. Pore formation is aided by interaction with cyclophilin D (CypD), Bax, as well as interactions with ANT ligands affecting its conformation. It is possible that other members from the mitochondrial carrier protein family fulfil a similar role as does ANT Bcl-2 by virtue of its capacity to create ion-permeant channels (Vander Heiden et al., 2001a) . Further studies are required to determine whether these two hypotheses regarding the contribution of VDAC to mitochondrial permeabilization are compatible (Figure 1b) .
Adenine nucleotide translocator (ANT) ANT, the most abundant IM protein, is responsible for the exchange of ATP and APD. ANT interacts with VDAC and other proteins, such as cyclophilin D, to form the permeability transition pore complex (PTPC) at the contact sites between IM and OM Crompton, 2000; Marzo et al., 1998) (Figure  2 ). ANT forms pores (Figure 1c ) that have been proposed to mediate the IM permeabilization, osmotic matrix swelling, and consequent selective OM rupture that occurs because the surface area of the IM (with its folded christae) exceeds that of the OM. Alternatively, the conformation of ANT, which is modulated by ANT ligands and CsA-inhibited interactions with cyclophilin D, might indirectly impinge on the function of VDAC.
Several pieces of data indicate that ANT is involved in apoptosis induction. Pro-apoptotic molecules such as Ca 2+ , palmitate, thiol oxidants, nitric oxide (NO), 4-hydroxynonenal, the protein Vpr encoded by HIV-1, as well as a synthetic peptide derived from the BH3 domain of Bax, cause ANT (which normally is a strictly specific antiporter: a transport protein specifically exchanging two molecules, in this case ATP and ADP, at a 1 : 1 stoichiometry) to form a non-specific pore . When reconstituted Figure 2 Hypothetical molecular architecture of the PTPC. The PTPC involves several transmembrane proteins (adenine nucleotide translocase, ANT; voltage dependent anion channel, VDAC; peripheral benzodiazepin receptor, PBR), members of the Bax/Bcl-2 family), as well as several associated proteins: hexokinase (HK), mitochondrial creatine kinase (mtCK), and the peptidyl-prolyl isomerase cyclophilin D (CypD). The reactions catalyzed by mtCK and HK are depicted. Pro-apoptotic second messengers, metabolites or processes labelled in green facilitate PTPC opening; agents in red inhibit pore opening. Proteins or peptides carrying the Bcl-2 homology region-3 (BH-3) motif may act on either Bax or Bcl-2 (or their homologues) in the outer mitochondrial membrane. Ca 2+ may act on VDAC, ANT, or ANT-associated cardiolipin (CL) molecules. Note that the exact stoichiometry and composition of the PTPC are still elusive into liposomes or into planar lipid bilayers, ANT can form non-specific channels in response to pro-apoptotic ligands such as atractryloside (a pro-apoptotic ANT inhibitor binding to the external site of ANT and favouring its conversion into a non-specific pore) and Vpr (a protein encoded by the HIV-1 genome).
ANT channel formation is also enhanced by Bax, but inhibited by Bcl-2 Jacotot et al., 2001; Marzo et al., 1998) . The ANT ligand bongkrekic acid (BA) inhibits cell death in numerous pathways , and CsA, which can prevent mitochondrial permeabilization in some circumstances, has also been proposed to exert its effect indirectly via ANT, by inhibiting its interaction with the matrix protein cyclophilin D (Crompton, 2000) .
Anti-apoptotic mitochondrial proteins It is well established that the anti-apoptotic oncoproteins Bcl-2 and Bcl-X L are mitochondrial membrane proteins that act as barriers to membrane permeabilization (Adams and Cory, 2001; Kroemer, 1997; Martinou and Green, 2001; Zamzami and Kroemer, 2001) . It is controversial, however, how they stabilize the membrane -it could be by neutralizing the function of pro-apoptotic Bcl-2 family proteins, by physically or functionally interacting with VDAC, by neutralizing ANT channel activity, or a combination of all of these. Some PTPC proteins (Figure 2 ) have also been reported to inhibit apoptosis. One of these is the peripheral benzodiazepine receptor (PBR) -an 18-kDa mitochondrial membrane protein that interacts with VDAC and ANT. PBR overexpression has been shown to be cytoprotective (Stoebner et al., 2001) . Hexokinase II, a mitochondrial protein that interacts with VDAC and catalyzes the first step of glycolysis, has also been shown to inhibit apoptosis. Hexokinase II transcription and mitochondrial localization are both induced by the Aktmediated anti-apoptotic signalling pathway (Gottlob et al., 2001; Vander Heiden et al., 2001b) . The enzymatic activity of hexokinase II might somehow inhibit apoptosis (Gottlob et al., 2001) , and, alternatively, this enzyme has also been proposed to impede VDAC-mediated membrane insertion of Bax (Pastorino et al., 2002).
Mitochondrial lipids
The lipid composition of the IM is very different from that of other intracellular membranes. The IM is essentially cholesterol-free, and is the only eukaryotic membrane to contain cardiolipin. IM contains a relatively high portion of negatively charged phospholipids such as phosphatidylserine. These characteristics might determine the preferential insertion of certain proteins into mitochondrial membranes. For example, t-Bid preferentially associates with cardiolipin-containing membranes (Lutter et al., 2000) , which might explain why t-Bid is enriched in the contact site between IM and OM. Cationic ampholytes -molecules that contain both a hydrophobic and a hydrophilic cationic moiety -might also be expected to preferentially redistribute to IM, driven not only by the DC m , but also due to the membrane presence of acidic phospholipids. It is important to note that the composition of mitochondrial lipids changes during apoptosis, with cardiolipin oxidation as a prominent feature (Matsko et al., 2001) . A local phospholipase A2 (Williams and Gottlieb, 2002) as well as a sphingomyelinase (Birbes et al., 2001 ) may increase the mitochondrial concentration of two potentially MMPinducing agents, namely arachidonic acid and ceramide, respectively. It remains an open question whether ceramide-induced lipid rafts in OM facilitate the insertion and oligomerization of Bax-like proteins, in analogy to what has been reported for CD95 in the plasma membrane (Gajate and Mollinedo, 2001 ).
Changes in mitochondrial ultrastructure As outlined above, the molecular control of MMP is complex and several distinct modes of MMP induction may exist. One particularly interesting feature that emerged from recent studies concerns mitochondrial ultrastructure. Thus, apoptosis is often associated with a disintegration of the mitochondrial reticulum into multiple punctiform organelles, a process which may require mitochondrial fission (Frank et al., 2001 ). In addition, it appears that, within mitochondria, the junctions between cristae and the intermembrane space are opened (Scorrano et al., 2002) , at least in some paradigms of apoptosis induction. Thus linking the exact topology of the multiple pore-forming and poreregulatory molecules (proteins+lipids) to the ultrastructural architecture of MMP regulation constitutes a challenge for future investigation.
Mitochondrial alterations in cancer
Do cancer cells also possess mitochondrial alterations that contribute to apoptosis resistance? A comparison of mitochondria isolated from tumour cells and normal cells revealed that 2-chlorodeoxyadenosine-resistant leukaemia cells harbour mitochondria that are intrinsically resistant to Ca 2+ -induced MMP (Chandra et al., 2002) . In fact, it has been known since the 1930's that cancer cell metabolism is different from that of normal cells. Cancer cells exhibit enhanced glycolytic ATP generation and decreased respiratory phosphorylation, even under normal oxygen tension -a phenomenon known as the Warburg effect (Warburg, 1956 ). This property is clinically important because it is taken advantage of in fluorine-18-deoxyglucose-positron emission tomography to detect tumours in vivo. The mechanism of tumour-associated aerobic glycolysis has not been fully elucidated, although it has been linked, at least speculatively, to an increase in hexokinase II expression (Golshani-Hebroni and Bessman, 1997) . In addition, tumour cells may have a higher DC m than control cells, although the biochemical basis of this phenomenon remains elusive (Chen, 1988) . These metabolic alterations might be linked to an overall change in the composition and/or regulation of the PTPC which would prevent mitochondrial apoptosis. Indeed, cancer cells reportedly overexpress some apoptosis-inhibitory PTPC components, such as hexokinase II and PBR) (Casellas et al., 2002; Smith, 2000) . They also undergo a shift in the ANT isoenzyme expression pattern, reducing expression of the potentially apoptogenic ANT-1 isoform and increasing the expression of ANT-2 (Giraud et al., 1998) .
Cancer cells also increase expression of anti-apoptotic Bcl-2-like proteins and reduce expression of proapoptotic proteins from the Bcl-2 family. Bax expression, for example, is downregulated as a consequence of genomic instability in colon carcinoma (Ionov et al., 2000) . A correlation between the expression levels of various apoptosis signalling proteins and clinical outcome has been well established (Kroemer, 1997) . The oncogenic property of some Bcl-2-like proteins, and the tumour-suppressive properties of Bcl-2 antagonists has been validated in animal models (Joza et al., 2002) . In addition, a number of alterations in the expression level of proteins closely linked to mitochondrial apoptosis may be relevant to cancer biology. This applies to pro-apoptotic proteins that may translocate to mitochondrial membranes (e.g. p53, c-Abl, Table 1 ), as well as to proteins which modulate the function of proteins released from mitochondria. For instance, the gene encoding Apaf-1, whose expression is required for cytochrome c to activate caspase-9, is frequently hypermethylated and therefore silenced in melanoma cells (Soengas et al., 2001) . Hsp70, which inactivates Apaf-1 and/or AIF (Ravagnan et al., 2001 ) is overexpressed in breast cancer.
The mitochondrial genome (mtDNA) is small (16.6 kb) and characterized by cytoplasmic transmission, so mutations can be transmitted to only a fraction of daughter cells after division (heteroplasmy) or to all of them (homoplasmy). Little is known about the association between mtDNA mutations and cancer. Whether mtDNA mutations or deletions accumulate due to active selection or due to random accumulation of one particular mitochondrial genome in rapidly dividing clones is a matter of debate (Coller et al., 2001) . Normal cells that lack mtDNA gene expression or carry mtDNA mutations may become hypersensitive to apoptosis induction (Danielson et al., 2002; . However, in several cancer cell lines, mtDNA mutations reportedly reduce the efficacy of chemotherapeutic agents, in particular of those agents which elicit the production of ROS by the respiratory chain (Hail et al., 2001; Singh et al., 1999) . It is therefore possible that mtDNA mutations contribute to chemotherapy resistance.
Cytotoxic drugs that target the mitochondria
The mere description that a given cytotoxic compound induces signs of MMP when added to intact cells does not yield any valuable information on its mode of action. Indeed, as discussed above, most, if not all, apoptosis inducers have such an effect, which mostly is mediated in an indirect fashion, through eliciting different ('intrinsic') stress pathways and/or the death receptor/ligand-dependent ('extrinsic') pathway. The only methodology which proves that a given drug exerts direct effects on mitochondria, is to show that the compounds actually induces MMP in a cell-free system, when added to purified mitochondria. Using such a system, a number of conventional chemotherapeutics have already been shown to induce cell death by permeabilizing mitochondrial membranes. These include 2-chloro-2'-deoxyadenosine, etoposide, and paclitaxel (Genini et al., 2000; Kidd et al., 2002; Robertson et al., 2000) . Paclitaxel has been suggested to act on VDAC-associated tubulin (Carre et al., 2002) . High doses of these drugs, however, are often required to obtain such effects. A number of other mitochondrion-permeabilizing drugs are being developed (Table  4) . What are the physicochemical and pharmacological properties of such mitochondrion-targeted agents?
Bcl-2-targeted drugs A number of reagents have been developed to target Bcl-2 family members, and might be able to induce apoptosis in cancer cells. For example, a recombinant chimeric protein that contains interleukin-2 fused to Bax has been shown to selectively kill interleukin-2 receptor-bearing cells in vitro (Aqeilan et al., 1999) . Similarly, Bak can be targeted to the Fce receptor by fusing it to the constant region of the immunoglobulin E molecule (Belostotsky and Lorberboum-Galski, 2001 ). This fusion protein has been shown to selectively induce apoptosis in Fce receptor-expressing cells in vitro, such as mast cells and basophils. These findings illustrate the feasibility of targeting pro-apoptotic proteins to selected cellular populations, although they have not yet been applied to the experimental treatment of cancer. An antisense oligonucleotide designed to down-regulate the expression of Bcl-2 (Genasense) has been shown to sensitize metastatic melanoma cells to apoptosis induction by dacarbazine in a phase I/II trial (Jansen et al., 2000) . Genasense is also being evaluated in a phase I study for the treatment of metastatic androgen-independent prostate cancer (Chi et al., 2001) . Such anti-sense oligonucleotides, which are relatively non-toxic to normal cells, might be particularly useful for treatment of tumours that express high levels of Bcl-2.
BH3 mimetics Several small molecules that disrupt the interaction between Bcl-X L and Bak-have been identified and shown to occupy the BH3-binding pocket (Box 1) of Bcl-X L . These molecules block the BH3-domain-mediated heterodimerization between Bcl-2 family members to induce apoptosis, presumably by acting as BH3 mimetics (Degterev et al., 2001) . The small molecule HA-14-1, which binds to the surface pocket of Bcl-2 can induce apoptosis in a similar manner . Antimycin A, a compound that inhibits complex III of the respiratory chain, and its methoxy derivative (which does not block complex III) also bind to the BH3-binding hydrophobic groove of Bcl-2 and Bcl-X L , thereby permeabilizing purified mitochondria expressing Bcl-X L (Tzung et al., 2001) . Peptides that correspond to the BH3 domains of Bax (BaxBH3) or Bcl-2 (Bcl2BH3) permeabilize mitochon-dria in a CsA-inhibitable fashion. When fused to the Atennapedia plasma membrane translocation domain (Ant), which facilitates cellular uptake, BaxBH3Ant and Bcl2BH3Ant induce mitochondrial permeabilization via a mechanism that is not inhibited by overexpressed Bcl-2 or Bcl-X L . Agents such as these might be used to overcome multidrug resistance in cancer cells that overexpress Bcl-2-like anti-apoptotic proteins.
PBR ligands Synthetic ligands of the PBR (such as the isoquinoline carboxamide PK 11195 or the benzodiazepine 4'-chlorodiazepam, Ro5-4864) can induce apoptosis or sensitize cells to apoptosis induction, thereby overcoming the cytoprotective effects of Bcl-2 or Bcl-X L . This chemosensitizing effect has been demonstrated in several tumour cell lines, in vitro (Banker et al., 2002; Decaudin et al., 2002; Hirsch et al., 1998) , and also in SCID mice transplanted with human tumour cells (Decaudin et al., 2002) . In these models, treatment with PBR ligands (such as PK 11195 or Ro5-4864) could not induce cell death on their own; but when used in combination with etoposide, cisplatin, arsenite, lonidamine, anti-CD95 antibody, dexamethasone or ceramide, these agents were cytotoxic and neutralized the anti-apoptotic potential of Bcl-2 (Banker et al., 2002; Decaudin et al., 2002; Hirsch et al., 1998) .
Whether the apoptogenic or chemosensitizing effects of PBR ligands are truly due to an effect on the PBR is a matter of debate (Banker et al., 2002) . The doses of PBR ligands required to obtain such cytotoxic effects are several orders of magnitude higher than the K d of the high affinity PBR. Hence, PBR ligands either act on a low affinity binding site present on mitochondria or via a completely different mechanism. Indeed, the pro-apoptotic action of PK11195 might involve the induction of ROS generation (Banker et al., 2002) . It will be important to resolve the issue as to whether expression of high PBR levels confers a higher susceptibility to PBR ligand-mediated chemosensitization. If this was the case, then PBR ligands might be particularly useful for the treatment of PBR overexpressing breast cancers (Casellas et al., 2002) . 
ANT ligands
A number of different reagents are able to permeabilize ANT-containing proteoliposomes, but not plain liposomes, so they might be used to specifically permeabilize mitochondrial membranes. These include cytotoxic drugs such as lonidamine, arsenite and CD437) (Belzacq et al., 2001a) , a peptide corresponding to the BH3 domain of Bax , and the HIV-1 protein Vpr . All these agents induce channel formation when ANT is reconstituted into planar lipid bilayers, but it is not known whether they act directly on ANT or on the ANT/lipid interface. They do, however, appear to induce a conformational change in ANT, since ANT proteoliposome permeabilization can be suppressed by the natural ANT ligands ATP and ADP (Belzacq et al., 2001a) . Whether the ATP analogue 2-chloro-2'-deoxyadenosine trisphosphate (generated from 2-chloro-deoxyadenosine by the action of the mitochondrial deoxyguanosine kinase) also acts on ANT is a matter of speculation. The bisphonate clodronate, which kills osteoclasts and is used for the palliative treatment of bone metastases, apparently is transformed into an ATP analogue which targets the ANT (Lehenkari et al., 2002) . MT-21, an ANT inhibitot, has been shown to dissociate the ANT-cylophilin complex in vitro and to induce cytochrome c in isolated mitochondria in a reaction that is inhibited by bongkrekic acid (Machida et al., 2002) . Lonidamine has been shown to revert the resistance to cisplatin and to potentiate cisplatin activity in experimental models. This drug is undergoing clinical phase II trials for the treatment of ovarian carcinoma (de Lena et al., 2001) . Lonidamine kills a diverse range of tumour cells in vitro (Angioli et al., 1997; Belzacq et al., 2001a) . However, the antiapoptotic proteins of the Bcl-2 family do confer a relative resistance to lonidamine that can be overcome by addition of PBR ligands (Miccoli et al., 1998b; Ravagnan et al., 1999) . Moreover, lonidamine (and arsenite) can bypass the resistance of TPAdifferentiated leukaemic cells to apoptosis in vitro (Sordet et al., 2001) , underscoring that direct targeting of mitochondria may be useful for the eradication of tumour cells. On theoretical grounds it is possible that ANT inhibitors might exhibit a selective toxicity on particular cell populations, depending on the expression of the ANT isoform and/or the mode of ANT operation (which is reversed in cells having respiratory defects). Thus, it might be conceivable to create ANT-specific agents that would selectively kill ANT2-overexpressing cancer cells or tumour cells having accumulated mutations in the mitochondrial genome.
Steroid analogues A number of agents that act on mitochondria possess a steroid-like core structure. This applies to avicins, betulinic acid, CD437 (a retinoid analogue), and the bile acid glycochenodesoxycholic acid. As a possibility, such agents might perturb the lipid composition of mitochondrial membranes, and induce the opening of the PTPC. Betulinic acid has the interesting (and unexplained) ability to selectively kill neuroectodermal tumour cells including neuroblastoma, medulloblastoma, glioblastoma and Ewing sarcoma cells (Fulda et al., 1998a,b; 2001; Fulda and Debatin, 2000) . Isolated mitochondria from different cell types, including from normal mouse liver, are permeabilized by betulinic acid, and this effect is prevented by CsA, the ANT ligand bongkrekate, as well as by Bcl-2 overexpression (Fulda et al., 1998b) . It is unclear, however, through which receptor (if any) betulinic acid acts on mitochondria and how the relative cell type specificity of betulinic acid can be explained. Nonetheless, it appears that derivatives of betulinic acid endowed with an enhanced in vivo half life might be useful in treating neuroectodermal tumours (Debatin et al., unpublished) .
Cationic ampholytes
The specific physicochemical properties of the IM and the net deficit of positive charges on the inner side of the IM results in the DC mdriven accumulation of cationic lipophils in the mitochondrial matrix. Following the Nernst equation, positively charged agents sufficiently lipophilic to insert in or to cross cellular membranes may be expected to enrich in IM and/or in the mitochondrial matrix. In fact, it might be expected that any compound with mild detergent-like properties would permeabilize mitochondria if it reached high enough concentrations in and around the IM. This molecular mode of action might apply to 2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride (FTY720), an immunosuppressive agent. MKT-077, a cationic rhodacyanine dye that is selectively toxic to carcinoma cells in vitro and in vivo (Modica-Napolitano et al., 1997) is now undergoing clinical trials (Britten et al., 2000) . Another cationic ampholyte is the peptide D KLAKLAKKLAKLAK or (KLAKLAK)2 (K=lysine, L=leucine, A=alanine) which directly permeabilizes mitochondria. D (KLAK-LAK) 2 can be fused to targeting peptides that interact with surface receptors expressed on angiogenic endothelial cells in tumours (Ellerby et al., 1999) or on prostate vasculature (Arap et al., 2002a) . These fusion peptides are translocated into the cytoplasm, and induce apoptosis via mitochondrial permeabilization (Ellerby et al., 1999) , specifically in the targeted cell population. Thus, a prostate-targeted D (KLAK-LAK) 2 peptide might be used to target prostate tumours in mice (Arap et al., 2002a) . Treatment of mice with this peptide postponed the development of cancer in a transgenic mouse model spontaneously developing prostate adenocarcinoma (Arap et al., 2002a) . Attempts to create peptides that would home to specific vascular beds are on the way in patients (Arap et al., 2002b) , and it is well possible that the strategy of targeting hybrid molecules, first to surface receptors and then to mitochondria, will become applicable to a variety of different tumours.
Redox-active compounds and photosensitizing agents
Agents that induce oxidative reactions can also be used to permeabilize the mitochondrial membrane. These agents include arsenite (which depletes glutathione), menadione (which undergoes futile redox cycles on the respiratory chain), as well as the thiolcrosslinking agent diamide, which is able to overcome cytoprotection by Bcl-2 and to cause thiol oxidation of ANT (Costantini et al., 2000a) . Arsenite, which permeabilizes purified mitochondria in vitro , is used to treat acute promyelomonocytic leukaemia and multiple myeloma. However, alternative mechanisms for the mode of action of arsenite such as lipid raft-linked signalling have been proposed (Hossain et al., 2000) .
Photosensitizing agents that act on mitochondriasome of which interact with PBR -generate ROS when exposed to light (Kessel et al., 2001 ). Locally generated ROS might then act on mitochondrial PTPC components including VDAC and ANT causing the formation of protein-permeable conduits (in the case of VDAC) (Madesh and Hajnoczky, 2001) or non-specific ion channels (in the case of ANT) (Belzacq et al., 2001b) . The photosensitizer hypericin reportedly detaches hexokinase from mitochondria (Miccoli et al., 1988a) , whereas the phthalocyanine photosensitizer Pc 4 causes the photochemical destruction of Bcl-2 (Xue et al., 2001) . Altogether, these data suggest that photosensitizing agents can target proteins contained in the PTPC.
Photodynamic therapy employing drugs that target mitochondria are likely to have high specificity for cancer cells but few side effects. This is particularly important for the treatment of surface cancers as well as for tumours that can be attained by the endoscopic delivery of light.
Clinical relevance of mitochondrial apoptotis
In vitro, all chemotherapeutic agents have been shown to induce apoptosis by causing mitochondrial permeabilization -characterized by the redistribution of mitochondrial intermembrane proteins (such as AIF or cytochrome c) and DC m collapse (Box 3). In vivo studies of apoptosis induction in experimental models or in patients undergoing therapy, however, have been limited to histological evaluation, providing a static picture of end stage apoptosis, rather than a real time observation of ongoing cell death. As a first attempt to monitor apoptosis induction in a real-time fashion, radioactive annexin-V has been employed to detect plasma membrane changes linked to apoptosis-induced chemotherapy in vivo. However, in vivo detection of apoptosis is hampered by the rapid clearance of apoptotic cells by phagocytes (Zhao et al., 2001) .
Since mitochondrial permeabilization is a relatively early event in the apoptotic program, methods to detect this process might be more useful in revealing the presence of apoptotic cells than other assays, such as those that measure caspase-3 activation or advanced DNA fragmentation -presumably because late-stage apoptotic cells are rapidly removed by phagocytosis. For example, in HIV-1-infected patients, a portion of circulating T lymphocytes exhibit a decreased DC m that is detectable ex vivo, when phosphotidylserine exposure, caspase activation or DNA fragmentation have not yet occurred (Macho et al., 1995) . Similarly, in pediatric patients receiving chemotherapy for the treatment of solid tumours, depletion of circulating CD4 + and CD8 + lymphocytes is preceded by a loss of DC m, detectable ex vivo (Stahnke et al., 2001) . Assays to measure mitochondrial membrane permeability might therefore be used to more accurately monitor the effects of chemotherapy.
Because MMP is the 'point of no return' in the apoptotic pathway, agents that induce it might be able to circumvent chemotherapy resistance caused by mutations in pre-mitochondrial signal-transducing machinery, such as the tumour suppressors p53 or PTEN. Accordingly, agents such as arsenite, betulinic acid, CD437, lonidamine and Vpr induce cell death independently of the p53 status, via a pathway that is not affected by caspase inhibitors Huang et al., 1999; Jacotot et al., 2001; Marchetti et al., 1999; Ravagnan et al., 1999; Sun et al., 1999) . Moreover, several mitochondrion-permeabilizing agents (in particular PBR ligands and BH3 mimetics) can induce apoptosis irrespective of the expression level of Bcl-2 (Banker et al., 2002; Decaudin et al., 2002; Hirsch et al., 1998; Tzung et al., 2001; Vieira et al., 2002) . Given that the composition and function of the PTPC from cancer cells differs from that of control, determining a relatively high DC m as well as the Warburg effect, even non-specific interventions on the PTPC (and mitochondria at large) could have selective effects on transformed cells.
Nonetheless, it will be a challenge to develop drugs with a strong mitochondrion-permeabilizing potential that selectively target tumour cells. Such targeting might be possible, however, by generating hybrid molecules composed of a mitochondriotoxic moiety fused to ligands for tumour cell surface proteins. As described above, this has been achieved, in principle, for the peptide D (KLAKLAK) 2 which, when fused to suitable ligands, specifically binds to target cells, becomes internalized and then acts on mitochondria. In the future, mitochondrion-targeted reagents might become a valuable tool for destroying cancer cells that have become resistant to the cytotoxic effects of conventional cancer therapies.
